Zongertinib Importer in India for Metastatic NSCLC

Lung cancer is one of the most commonly diagnosed cancers worldwide, and India continues to witness a rising number of cases every year. Among all lung cancer types, non-small cell lung cancer (NSCLC) accounts for nearly 85% of diagnosed lung cancer cases. Many patients are diagnosed at an advanced or metastatic stage, where the cancer spreads beyond the lungs to other parts of the body.

With advancements in precision oncology and targeted cancer therapies, newer treatment approaches are offering hope for patients with advanced lung cancer. One such emerging targeted therapy is Hernexeos (zongertinib).

This article explains how Hernexeos (zongertinib) may be accessed in India and how the Named Patient Program (NPP) works.

What is Zongertinib?

Zongertinib is approved for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations and who have received prior systemic therapy. Zongertinib is supplied under the brand Hernexeos.

Unlike traditional chemotherapy, targeted therapies are designed to act on specific cancer-related mutations or pathways involved in tumor growth. These therapies are becoming increasingly important in precision oncology because they help oncologists personalize treatment based on the patient’s molecular profile.

In advanced lung cancer treatment, molecular testing and biomarker analysis help identify patients who may benefit from targeted medicines like Zongertinib.

Understanding Metastatic Non-Small Cell Lung Cancer (NSCLC):

Metastatic NSCLC refers to lung cancer that has spread from the lungs to other organs, such as:

• Brain
• Bones
• Liver
• Adrenal glands
• Lymph nodes

Symptoms may include:

• Persistent cough
• Chest pain
• Fatigue
• Weight loss
• Shortness of breath
• Bone pain
• Coughing blood

Modern approaches for metastatic NSCLC treatment may include:

• Targeted therapy
• Immunotherapy
• Chemotherapy
• Personalized combination therapies

The introduction of targeted oncology medicines has transformed treatment strategies for many lung cancer patients worldwide.

Is Zongertinib Available in India?

Currently, Zongertinib in India is not yet available through regular pharmacy channels. However, Indian patients in India may still access Zongertinib through the Named Patient Program (NPP), subject to:

• Doctor prescription
• Regulatory approvals
• Import permissions
• Product availability from international sources

How to Access Zongertinib in India?

Currently, Zongertinib is not commercially available or approved for regular marketing in India. However, patients in India may still be able to access this medicine through the Named Patient Program (NPP).

The Named Patient Program is a legal pathway that allows the import of certain life-saving or innovative medicines that are unavailable in India, especially for patients with serious or life-threatening conditions such as metastatic non-small cell lung cancer (NSCLC).

In simple terms, the process works like this:

• A qualified oncologist prescribes the medicine for a specific patient
• Required medical and regulatory documents are prepared
• The medicine is sourced from international suppliers
• Import permissions and compliance procedures are followed under the Drugs and Cosmetics Act
• The medicine is imported specifically for that individual patient

This pathway helps patients access advanced global therapies when suitable treatment options may not be available locally.

The Named Patient Program is commonly used worldwide for innovative oncology medicines, rare disease therapies, and early-access treatments.

Documents Usually Required for Zongertinib Import in India:

To access Zongertinib in India through the Named Patient Program (NPP), certain medical and patient documents are generally required for regulatory and import procedures.
Commonly required documents may include:

• Signed and stamped prescription from a qualified treating doctor
• Copy of the doctor’s prescription mentioning the doctor’s registration number
• Patient’s medical case history and relevant treatment records
• Scan a copy of patient identification documents, such as:
• Passport
• Aadhaar Card
• Any valid government-issued photo ID

Our team helps coordinate the documentation process to support smooth patient-specific import procedures under applicable regulations.

Zongertinib Importer in India:

As Zongertinib is not yet commercially available in India, patients and hospitals often search for a reliable Zongertinib importer in India to help facilitate access to the medicine through legal import channels.

Eligible patients may import Zongertinib in India under the Named Patient Program with a valid doctor’s prescription and required regulatory documentation. Indian Pharma Network (IPN) helps support patients, caregivers, hospitals, and oncologists in the import process for Zongertinib in India.

As a trusted Hernexeos importer in India, Indian Pharma Network assists with:

• Named Patient Program support
• International medicine sourcing
• Regulatory documentation coordination
• Import process assistance
• Cold-chain and specialty logistics support
• Timely medicine access coordination

The process is handled in compliance with applicable import regulations and patient-specific requirements under the Drugs and Cosmetics Act.
Patients should always consult their treating oncologist before considering any advanced oncology treatment or the import process.

Typical Import Timeline for Zongertinib in India:

The estimated timeline for importing Zongertinib (Hernexeos) into India under the Named Patient Program is approximately 12–15 days.
The timeline may vary depending on:

• International product availability
• Regulatory documentation completion
• Shipping schedules
• Customs and import clearance procedures
• Cold-chain logistics coordination

Indian Pharma Network (IPN) works closely with patients, caregivers, hospitals, and international suppliers to help facilitate timely medicine access while maintaining compliance with applicable import regulations.

Need Help with Zongertinib Import in India?

Indian Pharma Network (IPN) supports patients, caregivers, hospitals, and healthcare professionals looking to import Zongertinib in India through the Named Patient Program (NPP).

Access to Zongertinib in India is subject to a doctor’s prescription, regulatory requirements, CDSCO regulations, and applicable import permissions. IPN supports hospitals and patients across Delhi, Mumbai, Gurgaon, Lucknow, Chennai, Bengaluru, Hyderabad, Kolkata, Pune, Ahmedabad, and other cities in India.

Important Note:
Zongertinib is a prescription-only medicine and should only be used under the supervision of a qualified oncologist.
Access and import are subject to:

• Doctor prescription
• Regulatory approvals
• Named Patient Program requirements
• Availability from international sources

Patients should always discuss treatment decisions with their healthcare provider.